skip to Main Content

We are developing

Tomorrow’s immuno – modulators oncology therapy
A single platform for defeating cancer and much more.

A single platform for defeating cancer

We are HEPHAISTOS-Pharma

A preclinical stage Biotech company developing the next generation of oncology treatments that will be boost immune system to treat incurable cancers.

One need, one mission :

Immunotherapy has shown impressive results in the past 5 years by treating cancers like never seen before. Unfortunately, success level are still very low and only 10% of patients can be cured today.

Our mission is to take Immunotherapy to the next level of efficiency by stimulating patients immune response and turning hidden cold tumors into hot targets for our immune system.

Founders

team-1

Chairwoman & CSO

Martine CAROFF
DSc., Inventor, TLR4 agonist biochemistry expert. EU Woman Innovators Prize 2019.

team-2

Immunology Expert

Pr. Jean-Marc CAVAILLON
Professor at Institut Pasteur, Innate Immunity expert.

team-3

CEO

Frederic CAROFF
MSc Centrale Paris, MBA Essec, Biotech Manager, Business Developer, Industrial scale up expert

team-4

CMC Manager

Alexey NOVIKOV
PhD, Head of Research Ability. Chemistry and Mass Spectrometry expert.

Other operational members

Jerome-Kerzerho-NB-190x190 (1)

Preclinical plan Manager

Jérôme KERZERHO
PhD, Immunologist, Collaborative project manager, Immuno-oncology expert.

Capucine_HQ

Research Officer

Capucine PHELIP-GONZALEZ
PhD, Immunologist, expert in animal experimentation

Simon PIco 2 NB

Business Developer

Simon PICO
PhD, MBA EMLyon, Biotech Ecosystem expert, Business Angel

Advisory Board

team-6

Pr. Charles Dumontet,
Deputy Director CRCL Physician in Hematology. Oncology KOL.

Pr. of Hematology in University of Lyon Deputy Director CRCL. President of the Clinical Research and Innovation Department and also Vice-President of Research at HCL

jean-yves-blay NB

Pr. Jean-Yves Blay,
General Director at the Centre Léon Bérard, Oncology KOL.

President of the French Federation of Cancer Centers Unicancer, coordinator of European Reference Network on rare adult cancers, EURACAN

team-5

Dr. Nathalie Garçon, Consultant, Adjuvant KOL

PharmD. PhD. Former CEO at BIOASTER, Former Vice President, Head of the Adjuvant and Technology Innovation Center at GSK Vaccines, 2014 Stanley Plotkin Award for lifetime achievement in vaccines

olivier favre-bulle NB

Dr. Olivier Favre-Bulle,
CEO at 3BIOTECH Consulting, CMC Expert

Chemical Engineer, Bio-engineering PhD, MBA, Former Project manager at Sanofi, Covanc,  Novo Nordisk, CMC Consultant.

Market Needs

Turning cold tumors into hot tumors

Only 10% of current immunotherapies are successful
Need for stronger and safer immuno-modulators
to turn cold tumors into hot tumors and improve cancer therapy

Innovation & advantages

Onco-Boost platform

ONCO-Boost is the Fisrt-In-Class Immunostimulant injectable intravenous able to treat metastatic and hardly accessible cancer like Osteorcoma

Mechanism of Action

Mechanism of Action (MoA)

ONCO-Boost

will stimulate monocytes, and dendritic cells to recruit and mature other immune defenses like CD4 T Cells, CD8 T Cells and macrophages.

Monoclonal
Antibody (mAb)

will block friendly recognition pathways between Tumor cells and host Cells allowing immune defenses to see Tumor as a target to destroy.

All together

By recruiting and stimulating immune cells, ONCO-Boost enable treatment of tumors that were not previously sensitive to mAb’s action and open the way to treat incurable cancers.

Pipeline

Immuno Oncology

ONCO-Boost Immunotherapy

Human Vaccine

VAXI-Boost natural adjuvant

News

HEPHAISTOS-Pharma secures a €2 million seed round

HEPHAISTOS-Pharma secures a €2 million seed round with…

Read more

HEPHAISTOS Laureate of the SANOFI Golden Ticket mRNA

  🏆 We are pleased to announce that…

Read more

EIC accelerator Grant Competition Winner

🏆  We are very proud to announce that…

Read more

iNov BPIFrance 2030 Competition Winner

🏆  We are very proud to announce that…

Read more

Clusters & Partners

Supports

HEPHAISTOS-Pharma is financed by the European Union FEDER regional fund

HEPHAISTOS-Pharma is financed by the WILCO Healthcare startup cluster.

HEPHAISTOS-Pharma is financed by the European Union and aims at becoming a breakthrough innovative Biotech in oncology, reaching clinical Phase 1 within 2 years. The ONCO-Boost project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 868937

HEPHAISTOS-Pharma’s academic partner CRCL is financed by the Region Auvergne-Rhône-Alpes, the Grand Lyon Metropole and the CLARA Canceropole.

Contact

    *

    *

    *

    *

    Back To Top